Detailed Narrative
Q4 FY26 Operational Performance
NOCIL reported Q4 FY26 revenue from operations at ₹330 crores, marking a sequential growth of 5%. Volumes also saw a positive trend, increasing by 7% sequentially. This growth was primarily driven by improved domestic demand following the implementation of GST 2.0, alongside steady single-digit growth in international markets. For the full year FY26, the company achieved an overall volume growth of 3%.
Profitability and Margin Compression
Despite volume growth, operating EBITDA for Q4 FY26 stood at ₹21 crores, a decline from ₹27 crores in Q3 FY26, with EBITDA margins shrinking to 6.4%. This compression was attributed to moderately higher utility costs, maintenance activities, and inventory depletion effects. For the full year, operating EBITDA was ₹101 crores (down from ₹137 crores in FY25), with a margin of 7.7%. PAT for Q4 FY26 was ₹17 crores, up from ₹9 crores in Q3 FY26, but full-year PAT declined significantly to ₹56 crores from ₹103 crores in FY25, partly due to a change in tax credits from the previous year.
Capex and Capacity Expansion Initiatives
The TDQ capex project at Dahej, announced in March 2024 and costing less than ₹250 crores, has been completed, and trial production has commenced. Samples are now being sent to customers for approval. Additionally, NOCIL announced another capex of ₹130 crores in March 2026, slated for completion by H1 FY28. This investment is for establishing a comprehensive integrated facility in the specialty rubber chemicals business, primarily for additional capacities and captive sales of intermediates.
Pricing Dynamics and Import Pressure
Realizations continued to face pressure in Q4 FY26 due to the ongoing dumping of lower-priced imports. Management noted that while input prices increased, finished goods prices also corrected. The company maintains a focus on balancing price and volume, with 65-70% of sales being contractual. Discussions with customers emphasize both supply reliability and competitive pricing, especially amidst global supply chain disruption🌐s.
Antidumping Duty (ADD) Update
The Director General of Trade Remedies (DGTR) has recommended positive final findings for antidumping duties on antioxidant TDQ and Sulphenamides (CBS and NS) in March 2026. These recommendations are awaiting central government approvals, which typically take around 90 days, expected by mid-June. Management highlighted that the impact of ADD is premature to comment on, as exporters may absorb duties, and the net effect on the industry needs to be analyzed.
Strategic Focus and Future Outlook
NOCIL aims for double-digit volume growth in the coming years and expects to improve its EBITDA by 150 basis points from the FY26 base. The company plans to increase its specialty segment mix to 20% post-commissioning of new capacities. Management is proactively monitoring geopolitical developments and managing supply chain disruption🌐s through calibrated inventory planning and diversified sourcing. Efforts are also underway to enhance operational efficiency and optimize costs, which contributed to cost control in FY26.
Working Capital Management and Debt Status
The company demonstrated strong working capital management, saving approximately ₹170-180 crores in FY26. This efficiency enabled NOCIL to fund its capex requirements without incurring new debt. As of the call date, NOCIL has not borrowed any debt, though it has access to credit lines exceeding ₹100 crores from banks, which will be utilized as needed.